Aronora, a Portland, OR-based clinical-stage biotech company, received an investment from NYBC Ventures.
The amount of the deal was not disclosed.
The company intends to use the funds for team expansion, manufacturing, and regulatory activities as they prepare for late-stage clinical development of their lead investigational products E-WE thrombin (AB002) and Gruticibart (AB023). Both drug candidates have completed phase 2a clinical trials, with compelling top-line data.
Founded by Dr. Andras Gruber and Dr. Erik Tucker, Aronora is a clinical-stage biotech focused on advancing blood clot treatment and prevention. Its work led to the filing of the first patents on coagulation factor XI inhibition, giving rise to antibody Gruticibart. This achievement marked the creation of an entirely new class of anti-factor XI blood thinners that are ready to transform the landscape of thrombosis treatment.
Aronora’s pipeline also includes a groundbreaking clot-buster, E-WE thrombin.
FinSMEs
16/10/2023